Search Results

Questions about how opioids impair breathing, why xylazine complicates interventions, and how receptor-level While writing a literature review on opioid and alcohol addiction susceptibility, something shifted. This approach makes her models not just rigorous, but translational—bridging the gap between receptor She is especially interested in mu-opioid receptor signaling  and how xylazine, as an alpha-2 adrenergic That personal loss transforms complex receptor pharmacology into something immediate and human.

Bigger Picture: GPCR Science Meets Public Health At its core, Catherine Demery’s research  is about receptors and signaling pathways—how mu-opioid  and alpha-2 adrenergic receptors  interact to disrupt breathing Fentanyl acts with devastating potency at the mu-opioid receptor , while xylazine exerts sedative effects Fentanyl, through the mu-opioid receptor, blunts the brainstem’s inspiratory drive so that each breath By displacing opioids from the mu-opioid receptor, it restores breathing within minutes.

There, she chose to write a review on genetic variation in susceptibility to alcoholism and opioid addiction—a Returning to the Opioid Questions That Mattered Now, as a PhD candidate in the Traynor and Anand labs at the University of Michigan, Catherine is focused on the mechanisms of opioid-induced respiratory "I've always been really passionate and somewhat sensitive to people who struggle with opioid abuse.

Home → Flash News → Can we preserve opioid pain relief without the side effects? Ep.166 of the Dr.GPCR Podcast, Ben Clements shares how positive allosteric modulators (PAMs) at the mu-opioid receptor could revolutionize treatment —with a 10x boost in methadone efficacy. Ep.166 of the Dr.GPCR Podcast, Ben Clements shares how positive allosteric modulators (PAMs) at the mu-opioid receptor could revolutionize treatment —with a 10x boost in methadone efficacy.

, receptors. investigates how fentanyl and xylazine shut down breathing through different mechanisms—work that blends receptor Listen now and see how one scientist is turning molecules into a mission, bridging the gap between receptor GPCR ecosystem , GPCR training program , GPCR podcast , opioid pharmacology , xylazine research , mu opioid receptor , pharmacogenomics , fentanyl epidemic , preclinical pharmacology Enjoying the Dr.

journey highlights the transition from general drug development to a deep dive into G protein-coupled receptors on positive allosteric modulators (PAMs) targeting opioid receptors. from the University of Minnesota in 2022, studying the pharmacokinetics and pharmacodynamics of NMDA receptor focuses on determining the mechanisms of action of a series of positive allosteric modulators of the mu-opioid receptor.